Corporate News Report
Henan Yuneng (001896.SZ)
Recent Trading Performance
Trading period: 24 hours ending at 08:11 PM Central Europe, Tuesday 20 th.
Price change: Flat 0 %.
Current trading price: CNY 9.66 on major exchanges.
Current supply: 1.5 billion shares.
Market capitalization: CNY 14.5 billion.
Turnover in last 24 hours: CNY 278.5 million.
Monthly change (since last month‑end): –20.61 %.
200‑day simple moving average: CNY 14.39.
52‑week high: CNY 24.04 (06/05/2026).
52‑week low: CNY 5.16 (12/31/2025).
Company Profile Henan Yuneng Holdings Co., Ltd. is a utility firm headquartered in Zhengzhou, China. The company generates and sells electric power and participates in environmental protection and energy‑conservation projects.
Related Stock Performance (last 24 hours)
| Ticker | Current Price | Market Cap | Recent Movement |
|---|---|---|---|
| Unicomp (688531.SS) | CNY 104.39 | CNY 17.3 bn | Flat 0 % |
| Inesa Intelligent Tech (600602.SS) | CNY 15.84 | CNY 17.3 bn | Flat 0 % |
| Shanghai Haoyuan Chemexpre (688131.SS) | CNY 86.25 | CNY 17.4 bn | Flat 0 % |
| Winner Medical (300888.SZ) | CNY 30.39 | CNY 17.3 bn | Flat 0 % |
| Shanghai Yuyuan Tourist Ma (600655.SS) | CNY 4.46 | CNY 17.3 bn | Flat 0 % |
Unicomp (688531.SS)
- Share‑repurchase plan announced by the chairman.
- Plan uses self‑funded and raised capital.
- Repurchased shares may be allocated to employee ownership or permanent capital reduction.
- Board approval required within a 12‑month horizon.
- Reflects a broader trend among hard‑technology listed firms to stabilize share prices and enhance shareholder value.
Inesa Intelligent Tech (600602.SS)
- Price‑to‑earnings ratio: 106.
Shanghai Haoyuan Chemexpre (688131.SS)
- Price‑to‑earnings ratio: 74.01.
- Strategic partnership with a major multinational pharmaceutical group.
- Deal includes upfront payment and milestone payments linked to antibody‑drug conjugate (ADC) development and commercialization.
- Indicates an industry shift toward joint‑venture agreements that provide cash flow and shared risk.
Winner Medical (300888.SZ)
- E‑commerce platform has gained >1.8 million followers.
- Focus on expanding medical retail segment through product upgrades and broader distribution.
- Shareholder return policy: maintain cash‑dividend ratio of at least 55 % over next three years; plan share‑repurchase of CNY 200–400 million.
- Overseas export sales grew modestly in H1; expects inventory pressure to ease in H2, supporting continued expansion.
Shanghai Yuyuan Tourist Ma (600655.SS)
- No additional commentary beyond flat trading and market capitalization.
Summary
Henan Yuneng’s trading activity remains stable with no price change during the reported 24‑hour period. The company’s market position is supported by a substantial share base and a significant market capitalization. Other listed firms in the technology, pharmaceutical, medical retail, and tourism sectors likewise experienced flat trading, with several announcing strategic initiatives such as share repurchase plans and international partnerships aimed at strengthening shareholder value and market presence.
